Needham & Company LLC Reaffirms Buy Rating for OncoCyte (NASDAQ:OCX)
Needham & Company LLC reiterated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $4.25 target price on the stock. Separately, StockNews.com initiated coverage on OncoCyte in a research report on Monday, January 13th. They issued a “sell” rating for the […]
Needham & Company LLC reiterated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $4.25 target price on the stock. Separately, StockNews.com initiated coverage on OncoCyte in a research report on Monday, January 13th. They issued a “sell” rating for the […]
